J. G. Klijn

Publication List Details

Period

1999 - 2008

Number

18

Co-Authors

A family history of breast cancer will not predict female early onset breast cancer in a population-based setting (2008)

De Bock, G.H., Jacobi, C.E., Seynaeve, C., Krol-Warmerdam, E.M., Blom, J., Van Asperen, C.J., ...

ABSTRACT: BACKGROUND: An increased risk of breast cancer for relatives of breast cancer patients has been demonstrated in many studies, and having a relative diagnosed with breast cancer at an early...

Association between the CHEK2*1100delC germ line mutation and estrogen receptor status (2006)

De Bock, G.H., Mourits, M.J., Schutte, M., Krol-Warmerdam, E.M., Seynaeve, C., Blom, J., ...

Already published data were further analyzed regarding the association between the CHEK2*1100delC germ line mutation and estrogen receptor (ER) status in patients with breast cancer. The...

Association between the CHEK2*1100delC germ line mutation and estrogen receptor status (2006)

De Bock, G.H., Mourits, M.J., Schutte, M., Krol-Warmerdam, E.M., Seynaeve, C., Blom, J., ...

Already published data were further analyzed regarding the association between the CHEK2*1100delC germ line mutation and estrogen receptor (ER) status in patients with breast cancer. The...

Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition (2004)

Kriege, M., Oosterwijk, J.C., Tilanus-Linthorst, M.M., Meijer, S., Koning, H.J. De, Muller, S.H., ...

BACKGROUND: The value of regular surveillance for breast cancer in women with a genetic or familial predisposition to breast cancer is currently unproven. We compared the efficacy of magnetic...

The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer (2003)

Foekens, J.A., Ries, C., Look, M.P., Gippner-Steppert, C., Klijn, J.G., Jochum, M.

A variety of serine proteases, including urokinase-type plasminogen activator (uPA), plasmin,and polymorphonuclear leukocyte elastase (PMN-E), have been implicated in the processes of tumor cell...

RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response (2003)

Burger, H., Foekens, J.A., Look, M.P., Klijn, J.G., Wiemer, E.A., ...

PURPOSE: The aim of this study was to investigate whether expression of particular drug resistance genes in primary operable breast cancer correlates with response to first-line chemotherapy in...

Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer (2003)

Berns, E.M., Portengen, H., Staveren, I.L. Van, Foekens, J.A., Sweep, F.C., ...

PURPOSE: In recent studies, we showed that TP53 gene mutation or high levels of cytosolic vascular endothelial growth factor (VEGF) in estrogen receptor (ER)-alpha-positive primary breast tumors...

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients (2002)

Look, M.P., Kueng, W., Klijn, J.G., Broet, P., Eppenberger U, Putten, W.L. Van, ...

BACKGROUND: Urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) play essential roles in tumor invasion and metastasis. High levels of both uPA and PAI-1 are associated with poor...

Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy (2001)

Foekens, J.A., Romain, S., Look, M.P., Martin, P.M., Klijn, J.G.

Thymidylate synthase (TS) is a crucial target for 5-fluorouracil (5-FU) in the de novo pathway of pyrimidine synthesis, which is necessary for DNA synthesis. Thymidine kinase (TK) plays a key role in...

High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer (2001)

Foekens, J.A., Peters, H.A., Grebenchtchikov, N., Look, M.P., Geurts-Moespot, A., ...

Vascular endothelial growth factor (VEGF), a potent angiogenic factor, has been reported to be associated with a poor prognosis in primary breast cancer and in several other cancer types. In the...

Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation (2001)

Meijers-Heijboer, H., Niermeijer, M.F., Klijn, J.G., Brekelmans, C.T., Geel, B. Van, Putten, W.L. Van, ...

BACKGROUND: Women with a BRCA1 or BRCA2 mutation have a high risk of breast cancer and may choose to undergo prophylactic bilateral total mastectomy. We investigated the efficacy of this procedure in...

Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment (2000)

Flier, S. Van Der, Brinkman, A., Look, M.P., Kok, E.M., Klijn, J.G., ...

BACKGROUND: The product of the Bcar1/p130Cas (breast cancer resistance/p130Crk-associated substrate) gene causes resistance to antiestrogen drugs in human breast cancer cells in vitro. To investigate...

The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients (2000)

Foekens, J.A., Henzen-Logmans, S.C., Klijn, J.G., Putten, W.L. Van, Peters, H.A., Look, M.P., ...

The antigen levels of components of the urokinase-type plasminogen activator (uPA) system of plasminogen activation are correlated with prognosis in several types of cancers, including breast cancer....

Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer (2000)

Berns, E.M., Cornelisse, C., Foekens, J.A., Vossen, R., Look, M.P., Klijn, J.G., ...

TP53 has been implicated in regulation of the cell cycle, DNA repair, and apoptosis. We studied, in primary breast tumors through direct cDNA sequencing of exons 2-11, whether TP53 gene mutations can...

Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study (2000)

Klijn, J.G., Piccart, M., Burghouts, J., Duchateau, L., Becquart, D., Mignolet, F., ...

BACKGROUND: Surgical or medical castration and antiestrogenic treatment with tamoxifen are common endocrine treatments for premenopausal women with breast cancer. However, tamoxifen therapy induces...

Presymptomatic testing for BRCA1 and BRCA2: how distressing are the pre-test weeks? Rotterdam/Leiden Genetics Working Group (1999)

Lodder, L.N., Devilee, P., Niermeijer, M.F., Cornelisse, C.J., Frets, P.G., Trijsburg, R.W., ...

Presymptomatic DNA testing for autosomal dominant hereditary breast/ovarian cancer (HBOC) became an option after the identification of the BRCA1 and BRCA2 genes in 1994-1995. Healthy female mutation...

Somatostatin receptors in differentiated ovarian tumors.

Reubi, J. C., Horisberger, U., Klijn, J. G., Foekens, J. A.

The presence of somatostatin receptors was investigated in 57 primary human ovarian tumors using in vitro receptor autoradiography with three different somatostatin radioligands,...